Bloomios

Bloomios Stock-Based Compensation

The Stock-Based Compensation (SBC) of Bloomios (BLMS) as of Nov 6, 2026 is -401,388.00 USD. In the previous year, Stock-Based Compensation (SBC) was 531,119.00 USD — a change of -175.57% (lower).

Stock-Based Compensation

-401,388.00USD

YoY

-175.57%

Last updated:

Stock-Based Compensation (SBC) of Bloomios is 2023 -401,388.00 USD. Stock-Based Compensation (SBC) of Bloomios was 2022 531,119.00 USD. It decreases by -175.57% lower compared to the previous year.

The Bloomios Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2021
277,333.00 USD
Jan 1, 2022
531,119.00 USD
Jan 1, 2023
-401,388.00 USD
The Bloomios Stock-Based Compensation history
YEARStock-Based CompensationYoY
-401,388.00USD-175.57%
531,119.00USD+91.51%
277,333.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bloomios Stock analysis

What does Bloomios do? Bloomios, Inc. generates revenue through the wholesale distribution of U.S. hemp-derived supplements and cosmetic products. The company manufactures and distributes hemp-infused edibles, pet edibles, tinctures, shots, topicals, smokable hemp, and other products across seven categories including edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. BPL, a subsidiary of Bloomios, focuses on manufacturing and distributing hemp-derived nootropic and nutraceutical products to wholesalers and retailers. Bloomios provides private-label and white-label services with over 80 customizable products and custom formulation and manufacturing support for its customers. The company's primary customers are wholesalers and retailers who purchase its hemp-derived products for resale. Bloomios offers a comprehensive suite of services including custom formulation, order fulfillment, and brand development to support its clients. Its product portfolio spans multiple categories such as human edibles, pet edibles, liquid consumables, topicals, and smokable hemp, catering to both consumer and pet markets. Bloomios leverages its subsidiary BPL to expand its product offerings in the hemp-derived nootropic and nutraceutical sectors. The company's focus on customizable solutions allows it to serve a diverse range of clients seeking private-label and white-label hemp products. Through its wholesale distribution channels, Bloomios targets businesses looking to sell hemp-based supplements and cosmetics under their own brand names. Bloomios is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bloomios stock

Stock-Based Compensation (SBC) of Bloomios is -401,388.00 USD in 2023.

Stock-Based Compensation (SBC) of Bloomios changed from 531,119.00 USD to -401,388.00 USD, representing a -175.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Bloomios since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Bloomios historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bloomios

All Key Metrics — Bloomios